Quantcast

Latest Clinical research Stories

2014-10-01 16:27:27

- BIO Investor Forum to be held October 7-8 in San Francisco - SAN DIEGO, Oct. 1, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today announced that it will be presenting at the 13(th) Annual BIO Investor Forum in San Francisco at the Palace Hotel. Paul Wagner, chief financial officer of Pfenex, will provide an overview of the...

2014-10-01 16:26:43

Global Clinical Trials Get Breakthrough Technology to Improve Signal Detection HAMILTON, N.J., Oct. 1, 2014 /PRNewswire/ -- MedAvante, Inc., the world's leading provider of technology-enabled signal detection solutions in clinical trials of treatments for central nervous system (CNS) disorders, announced the deployment of its groundbreaking Virgil Investigative Study Platform in multiple clinical trials worldwide. The Virgil platform, developed specifically for investigative sites,...

2014-10-01 12:31:51

--- CCPME is a fund jointly set up by the Caisse de dépôt et placement du Québec ("CDPQ") and by Capital régional et coopératif Desjardins ("CRCD") --- MONTREAL, Oct. 1(st) 2014 /CNW Telbec/ - JSS Medical Research Inc., a Montreal based Contract Research Organization (CRO), conducting Phase I - IV Clinical Trials, Post Marketing Observational Studies as well as Epidemiological and Health Economics Research for Pharmaceutical, Biotechnology and Device companies, announced today...

2014-10-01 12:31:29

SAN FRANCISCO, Oct 1, 2014 /PRNewswire/ -- In the world of mobile technology we have an app for everything, but mission-critical information about the clinical trials that physicians are managing seems to be in the prehistoric days. Clinical trials have inherently become more complex over the years, especially with infectious disease, cardiovascular, oncology and CNS trials. The number of vendors and pharmaceutical company contacts have soared - the average study has 30+ contacts...

2014-10-01 08:31:55

ANTWERP, Belgium and NEW YORK, October 1, 2014 /PRNewswire/ -- genae, a global Contract Research Organization (CRO) and service provider for the medical industries, announced today the expansion of its North American activities with the opening of offices in New York City. genae Americas was incorporated in 2011. "New York City is strategically centered in one of the highest concentrations of medical innovation and leading research facilities on the East Coast", said...

2014-10-01 08:31:32

BUENA, N.J., Oct. 1, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has acquired two previously marketed ophthalmic drug products, in addition to the right to acquire three additional previously marketed injectable drug products from affiliates of Valeant Pharmaceuticals International, Inc. after the completion of the due diligence process. All of these products have been approved by the FDA...

2014-10-01 08:30:24

-- Primary endpoint was met for 50 mg twice daily dosing -- FREMONT, Calif., Oct. 1, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). Results from this study demonstrated statistically significant and...

2014-09-30 23:24:57

On September 26, the FDA issued a safety communication on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) September 30, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Xolair...

2014-09-30 23:23:50

For generic drugmakers, Oct. 1 is crunch time, the date after which all ANDA amendment and prior-approval supplement applications must meet new performance goals under the Generic Drug User Fee Amendments (GDUFA) of 2012. Joan Janulis, a Hatch-Waxman pro and all-around expert on FDA regulation in the generic drug industry, will help attendees read between the lines of the GDUFA performance metrics, associated guidance documents and MAPPs, and provide a roadmap to the post-GDUFA paradigm....

2014-09-30 23:23:48

Having FDA-regulated products held at ports costs time, money and the competitive edge. Here’s the one interactive workshop that arms attendees with a full program of today’s best compliance strategies for speeding products out of Customs and into US and global markets. Falls Church, VA (PRWEB) September 30, 2014 Building a World-Class Import/Export Program: How to Comply with the FDA and US Customs **Presented Encore Insight LLC and FDAnews** Oct. 27-28, 2014 – Bethesda, MD...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related